Fabien Dorange holds a PhD in virology and worked as a postdoctoral researcher in the gene therapy field . Before joining Genethon, Fabien was Head of R&D viral safety in a CRO company (Texcell, France). He joined Genethon in 2016 and currently heads the analytical development department. He is responsible for developing analytical assays for characterization and release testing of gene therapy AAV vectors.
